DT2216 (DT-2216; DT 2216) is a novel and potent degrader of B-cell lymphoma extra large (BCL-XL) based on proteolysis-targeting chimera (PROTAC) technology. DT2216 exhibits anti-leukemia and anticancer activities by recruiting BCL-XL to the Von Hippel-Lindau (VHL) E3 ligase for degradation through the proteasome-dependent pathway.

纯度：≥98%

CAS：2365172-42-3